We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: chronic cough
MedXY News
EnglishTag

chronic cough

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled Trial
Clinical Updateschronic coughGabapentin

Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled Trial

By MedXY|Sep 1, 2026

A randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.

Brain Structure Changes in Chronic Cough: Insights from a Large-Scale Longitudinal Study
NeurologyneuroplasticityBrain Atrophy

Brain Structure Changes in Chronic Cough: Insights from a Large-Scale Longitudinal Study

By MedXY|Aug 11, 2026

This large-scale longitudinal study reveals that chronic cough is linked with widespread grey matter volume reductions and accelerated brain atrophy, highlighting potential neurostructural underpinnings of cough hypersensitivity.

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Internal Medicinechronic coughclinical trial

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

By MedXY|Jan 25, 2026

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications
Clinical Updateschronic cough

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications

By MedXY|Oct 8, 2025

The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential a

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities